Here at Adaptive, the fight against cancer is part of what motivates us and gives us a good bit of daily satisfaction with our work. This is why we are proud to support the Fred Hutchinson Cancer Research Center’s Obliteride … Continue reading
Yesterday, the Wall Street Journal addressed two early stage drug studies- one from Bristrol-Myers Squibb and one from Roche Holding AG. Both drug studies rely on the power of the patients’ immune system to fight the cancer they have been … Continue reading
We are proud to announce that Adaptive Biotechnologies successfully passed its recent CLIA audit with no deficiencies. This accomplishment paves the way for final validation of the clonoSEQ clinical assays for the monitoring of minimal residual disease (MRD). ClonoSEQ is … Continue reading
As chemotherapeutic treatment of patients with hematopoietic malignancies was emerging during the second half of the 20th century it became important to develop measurements and milestones of treatment efficacy. For decades the milestone of “remission” has included microscopic examination of … Continue reading
Yesterday, it was announced by SITC that Dr. Carl June would be receiving their most prestigious award at the Society’s Annual Meeting. In case you missed their email announcement, please see below. We are honored to be able to work … Continue reading
Today, Adaptive announced a partnership with Bristol Myers Squibb for the discovery of immunological biomarkers in cancer. The announcement was even picked up by the Wall Street Journal, whose press release can be read here. BMS is a pioneer and … Continue reading
Yesterday, a team of researchers from the University of Washington, Fred Hutchinson Cancer Research Center and Benaroya Research Institute published results from a study in which they used the immunoSEQ assay to identify the immune cells that suppress genital herpes … Continue reading
Yesterday, Science Daily announced a cool new device that can extract human DNA with full genetic data in minutes. The device is box shaped and handheld, and can extract DNA from fluid samples. Now, extracting DNA can be as easy … Continue reading
Because pancreatic cancer is often diagnosed after it has spread to other organs, treatment through chemotherapy, surgery, and radiotherapy are generally ineffective. Five-year survival is estimated at less than 5%, with no significant improvements in therapy in recent decades. In a mouse model … Continue reading
This week, two papers by the Cancer Genome Atlas Project (TCGA) consortium characterized genomes and epigenomic landscapes of two cancers: endometrial carcinoma (Nature) and adult de-novo acute myeloid leukemia (New England Journal of Medicine). Both studies describe molecular subtypes of … Continue reading
